<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-138090" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Regenerative Therapy in Pain</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Igwe</surname>
            <given-names>Nwadi</given-names>
          </name>
          <aff>Nuvance Health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Neil C.</given-names>
          </name>
          <aff>Nuvance Health Vassar Brothers Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Aijaz</surname>
            <given-names>Tabish</given-names>
          </name>
          <aff>Army Medical College</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nwadi Igwe declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Neil Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tabish Aijaz declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>16</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-138090.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Regenerative medicine involves delivering cells or cell products to tissues or organs that are diseased to restore tissue or organ function. Regenerative therapy in pain medicine involves various methods, such as viscosupplementation, stem cells, platelet-rich plasma, and prolotherapy, in the treatment and management of chronic pain. This activity describes and reviews the role of the interprofessional team in Improving care for chronic pain patients who undergo regenerative therapy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for regenerative pain medicine therapies.</p></list-item><list-item><p>Describe the technique of regenerative pain medicine therapies.</p></list-item><list-item><p>Explain the most common therapy-specific complications and adverse effects associated with regenerative pain medicine.</p></list-item><list-item><p>Outline the clinical significance of regenerative pain medicine.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=138090&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=138090">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-138090.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Regenerative medicine has been in existence for many decades, and many therapies have received United States Food and Drug Administration (FDA) approval for wound healing and orthopedic applications. Regenerative medicine is a field that applies biological science principles to promote regeneration by delivering or replacing&#x000a0;organs, cells, or tissues in an attempt to restore diseased and damaged tissues and whole organs.<xref ref-type="bibr" rid="article-138090.r1">[1]</xref>&#x000a0;There are four main avenues of therapies in regenerative medicine: viscosupplementation, platelet-rich plasma, stem cells, and prolotherapy.&#x000a0;&#x000a0;</p>
        <p><bold>Viscosupplementation:</bold> Injection of hyaluronic acid into intra-articular space can restore the viscosity and elasticity of osteoarthritic synovial fluid.<xref ref-type="bibr" rid="article-138090.r2">[2]</xref><xref ref-type="bibr" rid="article-138090.r3">[3]</xref>&#x000a0;HA plays an essential role in shock absorption, lubrication, and the&#x000a0;visco-elastic nature of the synovial fluid.&#x000a0;&#x000a0;&#x000a0;&#x000a0;</p>
        <p><bold>Prolotherapy:</bold> Prolotherapy is the injection of a solution to rehabilitate an incompetent structure and promote sclerosis at the injection site.<xref ref-type="bibr" rid="article-138090.r4">[4]</xref><xref ref-type="bibr" rid="article-138090.r5">[5]</xref>&#x000a0;Prolotherapy differs from other regenerative medicine techniques because the injectate lacks a biological component. The most commonly used injectate for prolotherapy is hypertonic dextrose which causes a stimulation of the body&#x02019;s inflammatory cascade.<xref ref-type="bibr" rid="article-138090.r6">[6]</xref><xref ref-type="bibr" rid="article-138090.r5">[5]</xref>&#x000a0;</p>
        <p><bold>Platelet-rich plasma:</bold> Platelet-rich plasma releases bioactive proteins that&#x000a0;stimulate the body&#x02019;s ability to heal due to its regenerative, analgesic, and anti-inflammatory properties.&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;</p>
        <p>
<bold>Mesenchymal Stem Cell</bold>
</p>
        <p>According to the International Society for Cellular Therapy, the criteria for cells to be considered mesenchymal stem cells include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Plastic adherence when maintained under standard culture</p>
          </list-item>
          <list-item>
            <p>Expression of CD73, CD 90, and CD 105 and not the expression of CD11b, CD14, CD19, CD34, CD45, or HLA-DR</p>
          </list-item>
          <list-item>
            <p>Ability to differentiate into osteoblasts, chondroblasts, and adipocytes in vitro&#x000a0;<xref ref-type="bibr" rid="article-138090.r7">[7]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-138090.s3" sec-type="Indications">
        <title>Indications</title>
        <p><bold>Viscosupplementation:</bold> Viscosupplementation is currently FDA-approved for the treatment of knee osteoarthritis (OA). It is indicated for patients in whom conservative therapies such as physical therapy, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroid injections, and aspiration fail. Elderly patients with any stage of OA are good candidates for viscosupplementation. Younger patients with mild to moderate knee OA who have clinical symptoms but are not ready for invasive surgical intervention are also good candidates.</p>
        <list list-type="bullet">
          <list-item>
            <p>Viscosupplementation is also useful in patients with Kellgren-Lawrence stages 1 to 3. Patients with stage 4 OA who want to delay total knee replacement are ideal for viscosupplementation. It can also be used as first-line therapy in patients with multiple comorbidities who are on multiple medications to avoid the side effects of anti-arthritic drugs. It can be considered in patients who cannot take NSAIDs due to gastrointestinal or renal disease or unstable hypertension.</p>
          </list-item>
        </list>
        <p><bold>Prolotherapy:</bold> Indications for Prolotherapy include OA and degenerative syndromes, myofascial pain syndrome, spine and pelvic pain, refractory tendinopathies, and plantar fasciitis.<xref ref-type="bibr" rid="article-138090.r4">[4]</xref><xref ref-type="bibr" rid="article-138090.r5">[5]</xref><xref ref-type="bibr" rid="article-138090.r6">[6]</xref>&#x000a0;Some study results have shown that hypertonic dextrose promotes direct intracellular expression of growth factors in tenocytes and fibroblasts.<xref ref-type="bibr" rid="article-138090.r8">[8]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>The goal of&#x000a0;prolotherapy is the stimulation of the body's healing process in the joint to facilitate improvement in the tensile strength of the joint stabilizing structures. Hypertonic dextrose acts by dehydrating the cells at the site of injections, whichcauses local tissue trauma, which attracts granulocytes and macrophages to promote healing. Studies on human fibroblasts and chondrocytes have shown that extracellular dextrose concentrations result in the proliferation and production of essential growth factors for tissue repair. These growth factors promote the expression of type 1 and type 3 collagen in tenocytes, which is essential for the growth of tendons, ligaments, and cartilage.<xref ref-type="bibr" rid="article-138090.r6">[6]</xref><xref ref-type="bibr" rid="article-138090.r8">[8]</xref></p>
          </list-item>
        </list>
        <p><bold>Plasma-rich platelets:</bold> Platelet-rich plasma (PRP) is currently used to treat OA, ligament injury, meniscus injury, muscle injury, tendinopathy, and spine disorders. There are numerous methods of preparing PRP. Due to variability in the methods of PRP preparations, there is no universal classification system. However, PRP is mainly categorized into 2 classifications: leukocyte-rich PRP (LR-PRP) and leukocyte-poor PRP (LP-PRP). LR-PRP has neutrophil counts above baseline and thus is associated with pro-inflammatory effects.<xref ref-type="bibr" rid="article-138090.r9">[9]</xref>&#x000a0;Data suggests that LR-PRP is superior for tendinopathy, and LP-PRP is more effective for OA.<xref ref-type="bibr" rid="article-138090.r10">[10]</xref><xref ref-type="bibr" rid="article-138090.r11">[11]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>PRP has piqued the scientific community's interest due to its various properties, such as regenerative, analgesic, anti-microbial, and anti-inflammatory.<xref ref-type="bibr" rid="article-138090.r12">[12]</xref>&#x000a0;Platelets are nuclear, cytoplasmic fragments of megakaryocytes. The initial steps in the process of wound healing involve platelet activation, adhesion, and aggregation. After the activation phase, alpha granules in the platelets degranulate and release multiple growth factors and cytokines. PRP contains more than 300 growth factors and cytokines, which are involved in cell proliferation, tissue remodeling, enhancement of mitogenesis, extracellular matrix synthesis, mesenchymal differentiation, and suppressing inflammation&#x02014;which play an important role in wound healing.<xref ref-type="bibr" rid="article-138090.r13">[13]</xref>&#x000a0;PRP delivers supraphysiologic concentrations of these molecules to an injury site to promote tissue remodeling, repair, and regeneration.<xref ref-type="bibr" rid="article-138090.r14">[14]</xref></p>
          </list-item>
        </list>
        <p><bold>Mesenchymal stem cells:</bold> The indications for mesenchymal stem cells (MSCs) vary depending on the harvest site. Sources of MSCs include bone marrow, adipose tissue, umbilical cord, muscle, peripheral blood, and amniotic fluid.<xref ref-type="bibr" rid="article-138090.r15">[15]</xref>&#x000a0;Specific indications for bone marrow-derived MSCs include treatment of osteonecrosis of the femoral head and OA of the shoulder. It can also be used for rotator cuff and patellar tendinopathy. Adipose-derived MSCs can be used for lateral epicondylitis and Achilles tendinopathy. Amniotic-derived MSCs can be used for plantar fasciitis.</p>
      </sec>
      <sec id="article-138090.s4" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications differ depending on the method of regenerative medicine that is employed. General contraindications include active infection, either systemic or at the injection site, and coagulopathy.<xref ref-type="bibr" rid="article-138090.r16">[16]</xref>&#x000a0;Therapy-specific contraindications include venous stasis, Hylan allergy, and allergy to eggs for viscosupplementation, as some of the products are derived from rooster combs.<xref ref-type="bibr" rid="article-138090.r17">[17]</xref>&#x000a0;Stem cell therapy should be avoided in patients with bone marrow-derived cancers or immunocompromised states.<xref ref-type="bibr" rid="article-138090.r18">[18]</xref>&#x000a0;</p>
        <p>Absolute contraindications of PRP administrations are critical thrombocytopenia, platelet dysfunction syndrome, and hemodynamic instability. Relative contraindications include bone or blood cancer, anemia, regular NSAID use within 48 hours of the procedure, corticosteroid injection of the knee within one month, or systemic steroid use within two weeks.<xref ref-type="bibr" rid="article-138090.r19">[19]</xref>&#x000a0;Absolute contraindications for prolotherapy include active rheumatological disorders, corn allergy, or immunosuppressive therapy.<xref ref-type="bibr" rid="article-138090.r5">[5]</xref></p>
      </sec>
      <sec id="article-138090.s5" sec-type="Technique or Treatment">
        <title>Technique or Treatment</title>
        <p><bold>Viscosupplementation:</bold> Hyaluronic acid (HA) injection can be done in the office and is usually a quick procedure typically performed under Local anesthesia. Usually, 2&#x000a0;to 4 mL of HA should be injected directly into the joint capsule to be effective. Patients are advised to avoid excessive weight-bearing in the first 48 hours after the injections. Physical therapy is recommended afterward to improve functioning and range of motion.</p>
        <p><bold>Prolotherapy:</bold> The most commonly used agent for prolotherapy is dextrose; concentrations greater than 10% are considered inflammatory, while those lower than 10% are considered noninflammatory.<xref ref-type="bibr" rid="article-138090.r6">[6]</xref>&#x000a0;Dextrose proliferates are approved by the FDA for injections but not for prolotherapy. Its current use for prolotherapy is off-label.</p>
        <p><bold>Plasma-rich platelets:</bold> PRP is obtained from the patient&#x02019;s blood using the two-step centrifugation method. The first step separates whole blood into platelet and cell fractions. The second centrifugation step is performed at a higher speed. It further separates platelet growth factors. The final concentration range for the PRP product is 1.5 to 8 times the whole blood. It is usually activated by calcium chloride, bovine thrombin, or autologous thrombin.</p>
        <p><bold>Mesenchymal stem cells:</bold> About 60 mL of bone marrow aspirate is collected and centrifuged to produce about 6 mL of bone marrow aspirate concentrate. MSCs are multipotent and can be harvested from several tissues, eg, bone marrow, adipocytes, and amniotic tissue. The usual location for bone marrow aspiration is the iliac crest under anesthesia due to the associated pain and discomfort with the harvest.<xref ref-type="bibr" rid="article-138090.r18">[18]</xref></p>
      </sec>
      <sec id="article-138090.s6" sec-type="Complications">
        <title>Complications</title>
        <p>Regenerative therapy is generally well tolerated. The most common side effects are injection site swelling, pain or soreness, or stiffness.<xref ref-type="bibr" rid="article-138090.r20">[20]</xref><xref ref-type="bibr" rid="article-138090.r21">[21]</xref>&#x000a0;Therapy-specific complications include hemarthrosis, septic arthritis, seizures, pulmonary embolism, and anaphylactic reactions. However, these more severe side effects are extremely rare. Stem cell therapy is very well tolerated, with most patients reporting satisfaction with the procedure. Other reported side effects include low-grade fevers.<xref ref-type="bibr" rid="article-138090.r22">[22]</xref><xref ref-type="bibr" rid="article-138090.r23">[23]</xref>&#x000a0;</p>
        <p>Complications of PRP injections are extremely rare. Since PRP is an autologous product, the chance of having an allergic or immune reaction is&#x000a0;non-existent. The most common side effect includes local site infection and pain at the injection site. Historically, bovine thrombin&#x000a0;serves as an activator in some commercially available PRP kits. It carries a potential risk of coagulopathy. When bovine thrombin is used as an activator, patients develop antibodies to bovine factor V and bovine thrombin itself. When factor V level decreases below 30%, the risk of hemorrhage increases in patients; for this reason, autologous thrombin or recombinant human thrombin is available as an activator.<xref ref-type="bibr" rid="article-138090.r24">[24]</xref><xref ref-type="bibr" rid="article-138090.r25">[25]</xref>&#x000a0;Rare adverse effects of prolotherapy reported include sleep disturbance, radicular pain, irregular menstruation, and lumbar puncture headache. Other even rarer effects reported include meningitis, adhesive arachnoiditis, and encephalomyelitis.<xref ref-type="bibr" rid="article-138090.r26">[26]</xref><xref ref-type="bibr" rid="article-138090.r27">[27]</xref></p>
      </sec>
      <sec id="article-138090.s7" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Multiple systemic reviews and meta-analyses have shown that intra-articular knee HA injections are safe, decrease pain, and improve function in patients.<xref ref-type="bibr" rid="article-138090.r28">[28]</xref><xref ref-type="bibr" rid="article-138090.r29">[29]</xref><xref ref-type="bibr" rid="article-138090.r30">[30]</xref><xref ref-type="bibr" rid="article-138090.r31">[31]</xref>&#x000a0;A Cochrane database review of 76 trials concluded that HA is a safe and efficacious option for knee OA.<xref ref-type="bibr" rid="article-138090.r32">[32]</xref>&#x000a0;It showed improved pain and functional status for up to 26 weeks. Prolotherapy offers a cost-effective and conservative approach to the treatment of chronic pain. Several studies have shown the efficacy of prolotherapy for treating pain and dysfunction associated with various chronic musculoskeletal conditions, especially tendinopathies and OA.&#x000a0;Further studies are needed to determine a standard protocol for prolotherapy injections.&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;</p>
        <p>PRP is currently used as a treatment modality for OA, ligament injury, meniscus injury, muscle injury, tendinopathy, and spine disorders. Multiple randomized control trials, systemic reviews, and meta-analyses have supported the use of PRP in the management of chronic tendinopathy. However, variations in PRP preparation methods, post-intervention rehabilitation protocol, and different anatomic sites translate into variations in the outcomes of the studies.<xref ref-type="bibr" rid="article-138090.r33">[33]</xref><xref ref-type="bibr" rid="article-138090.r34">[34]</xref><xref ref-type="bibr" rid="article-138090.r35">[35]</xref>&#x000a0;LP-PRP has improved pain and functional status for knee OA patients. Some studies have shown symptom relief for&#x000a0;up to 1 year after PRP injection for knee OA. Patients in earlier stages of knee OA may benefit more from PRP than HA injections. Studies have not shown any significant benefits of PRP in treating hip OA.<xref ref-type="bibr" rid="article-138090.r36">[36]</xref><xref ref-type="bibr" rid="article-138090.r37">[37]</xref></p>
        <p>Many studies have examined the efficacy of PRP for the treatment of ligament injuries. There is promising evidence that PRP can improve anterior cruciate ligament reconstruction outcomes.<xref ref-type="bibr" rid="article-138090.r38">[38]</xref>&#x000a0;Even though PRP has been used in clinical practice as a non-operative treatment for ligament injuries, a higher level of literature is scarce to prove any benefit or safety profile of PRP for ligament injuries.<xref ref-type="bibr" rid="article-138090.r39">[39]</xref></p>
        <p>Low back pain is very prevalent among US adults and is one of the most common debilitating outpatient complaints.<xref ref-type="bibr" rid="article-138090.r40">[40]</xref>&#x000a0;Many researchers have focused on PRP as a treatment modality for low back pain associated with disc degeneration and facet joint osteoarthritis. Recent in vitro studies have shown PRP to stimulate proliferation and matrix synthesis in annulus fibrosus and nucleus pulposus. It exhibits anti-inflammatory effects on nucleus pulposus cells as well.<xref ref-type="bibr" rid="article-138090.r41">[41]</xref><xref ref-type="bibr" rid="article-138090.r42">[42]</xref><xref ref-type="bibr" rid="article-138090.r43">[43]</xref>&#x000a0;</p>
        <p>Despite promising in-vitro results, very few high-quality clinical studies have been done to evaluate the role of PRP in the treatment of low back pain.<xref ref-type="bibr" rid="article-138090.r44">[44]</xref><xref ref-type="bibr" rid="article-138090.r45">[45]</xref> Multiple small-scale studies have shown PRP to be safe and beneficial in treating discogenic and facet joint-related back pain. Still, more high-quality studies are needed to prove the efficacy of PRP for spine disorders.<xref ref-type="bibr" rid="article-138090.r46">[46]</xref><xref ref-type="bibr" rid="article-138090.r47">[47]</xref><xref ref-type="bibr" rid="article-138090.r48">[48]</xref>&#x000a0;A review of various studies involving the use of bone marrow concentrate in treating musculoskeletal disorders of the knee has shown level II evidence in the treatment of knee OA.<xref ref-type="bibr" rid="article-138090.r49">[49]</xref></p>
      </sec>
      <sec id="article-138090.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>All the regenerative therapies discussed are best administered by an interprofessional healthcare team, sharing information, keeping each other informed regarding patient status changes post-procedure, and empowered to offer their view on the case without fear of reprisal. This interprofessional approach will create the environment for optimal patient outcomes with the fewest adverse events.</p>
      </sec>
      <sec id="article-138090.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=138090&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=138090">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/138090/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=138090">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-138090.s10">
        <title>References</title>
        <ref id="article-138090.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mao</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Mooney</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Regenerative medicine: Current therapies and future directions.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2015</year>
            <month>Nov</month>
            <day>24</day>
            <volume>112</volume>
            <issue>47</issue>
            <fpage>14452</fpage>
            <page-range>14452-9</page-range>
            <pub-id pub-id-type="pmid">26598661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henrotin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Raman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Richette</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bard</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jerosch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Conrozier</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chevalier</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Migliore</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Consensus statement on viscosupplementation with hyaluronic acid for the management of osteoarthritis.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>45</volume>
            <issue>2</issue>
            <fpage>140</fpage>
            <page-range>140-9</page-range>
            <pub-id pub-id-type="pmid">26094903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balazs</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Denlinger</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Viscosupplementation: a new concept in the treatment of osteoarthritis.</article-title>
            <source>J Rheumatol Suppl</source>
            <year>1993</year>
            <month>Aug</month>
            <volume>39</volume>
            <fpage>3</fpage>
            <page-range>3-9</page-range>
            <pub-id pub-id-type="pmid">8410881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dagenais</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yelland</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Del Mar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schoene</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Prolotherapy injections for chronic low-back pain.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2007</year>
            <month>Apr</month>
            <day>18</day>
            <volume>2007</volume>
            <issue>2</issue>
            <fpage>CD004059</fpage>
            <pub-id pub-id-type="pmid">17443537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siadat</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Isseroff</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Prolotherapy: Potential for the Treatment of Chronic Wounds?</article-title>
            <source>Adv Wound Care (New Rochelle)</source>
            <year>2019</year>
            <month>Apr</month>
            <day>01</day>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>160</fpage>
            <page-range>160-167</page-range>
            <pub-id pub-id-type="pmid">31646060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hauser</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Lackner</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Steilen-Matias</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>A Systematic Review of Dextrose Prolotherapy for Chronic Musculoskeletal Pain.</article-title>
            <source>Clin Med Insights Arthritis Musculoskelet Disord</source>
            <year>2016</year>
            <volume>9</volume>
            <fpage>139</fpage>
            <page-range>139-59</page-range>
            <pub-id pub-id-type="pmid">27429562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dominici</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Le Blanc</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Slaper-Cortenbach</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Marini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Krause</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Deans</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Prockop</surname>
                <given-names>Dj</given-names>
              </name>
              <name>
                <surname>Horwitz</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.</article-title>
            <source>Cytotherapy</source>
            <year>2006</year>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>315</fpage>
            <page-range>315-7</page-range>
            <pub-id pub-id-type="pmid">16923606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vora</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Borg-Stein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Regenerative injection therapy for osteoarthritis: fundamental concepts and evidence-based review.</article-title>
            <source>PM R</source>
            <year>2012</year>
            <month>May</month>
            <volume>4</volume>
            <issue>5 Suppl</issue>
            <fpage>S104</fpage>
            <page-range>S104-9</page-range>
            <pub-id pub-id-type="pmid">22632688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dragoo</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Durham</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Ridley</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Odegaard</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Luong</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arnoczky</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the acute inflammatory response of two commercial platelet-rich plasma systems in healthy rabbit tendons.</article-title>
            <source>Am J Sports Med</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>1274</fpage>
            <page-range>1274-81</page-range>
            <pub-id pub-id-type="pmid">22495144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fitzpatrick</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bulsara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>The Effectiveness of Platelet-Rich Plasma in the Treatment of Tendinopathy: A Meta-analysis of Randomized Controlled Clinical Trials.</article-title>
            <source>Am J Sports Med</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>226</fpage>
            <page-range>226-233</page-range>
            <pub-id pub-id-type="pmid">27268111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Braun</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Dragoo</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>The effect of platelet-rich plasma formulations and blood products on human synoviocytes: implications for intra-articular injury and therapy.</article-title>
            <source>Am J Sports Med</source>
            <year>2014</year>
            <month>May</month>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>1204</fpage>
            <page-range>1204-10</page-range>
            <pub-id pub-id-type="pmid">24634448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harrison</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cramer</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Platelet alpha-granules.</article-title>
            <source>Blood Rev</source>
            <year>1993</year>
            <month>Mar</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>52</fpage>
            <page-range>52-62</page-range>
            <pub-id pub-id-type="pmid">8467233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coppinger</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cagney</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Toomey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kislinger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Belton</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>McRedmond</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Cahill</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Emili</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Maguire</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <article-title>Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions.</article-title>
            <source>Blood</source>
            <year>2004</year>
            <month>Mar</month>
            <day>15</day>
            <volume>103</volume>
            <issue>6</issue>
            <fpage>2096</fpage>
            <page-range>2096-104</page-range>
            <pub-id pub-id-type="pmid">14630798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Sharkawy</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kantarci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Deady</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hasturk</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Alshahat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van Dyke</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Platelet-rich plasma: growth factors and pro- and anti-inflammatory properties.</article-title>
            <source>J Periodontol</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>78</volume>
            <issue>4</issue>
            <fpage>661</fpage>
            <page-range>661-9</page-range>
            <pub-id pub-id-type="pmid">17397313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Veronesi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Giavaresi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tschon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Borsari</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Nicoli Aldini</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fini</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical use of bone marrow, bone marrow concentrate, and expanded bone marrow mesenchymal stem cells in cartilage disease.</article-title>
            <source>Stem Cells Dev</source>
            <year>2013</year>
            <month>Jan</month>
            <day>15</day>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>181</fpage>
            <page-range>181-92</page-range>
            <pub-id pub-id-type="pmid">23030230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <collab>Medical Advisory Secretariat</collab>
            <article-title>Intra-articular viscosupplementation with hylan g-f 20 to treat osteoarthritis of the knee: an evidence-based analysis.</article-title>
            <source>Ont Health Technol Assess Ser</source>
            <year>2005</year>
            <volume>5</volume>
            <issue>10</issue>
            <fpage>1</fpage>
            <page-range>1-66</page-range>
            <pub-id pub-id-type="pmid">23074461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Axe</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Snyder-Mackler</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Axe</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>The role of viscosupplementation.</article-title>
            <source>Sports Med Arthrosc Rev</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-22</page-range>
            <pub-id pub-id-type="pmid">23314264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chahla</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mannava</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cinque</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Geeslin</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Codina</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>LaPrade</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Bone Marrow Aspirate Concentrate Harvesting and Processing Technique.</article-title>
            <source>Arthrosc Tech</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>e441</fpage>
            <page-range>e441-e445</page-range>
            <pub-id pub-id-type="pmid">28580265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Gulati</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Platelet-rich plasma: a healing virtuoso.</article-title>
            <source>Blood Res</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>51</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-5</page-range>
            <pub-id pub-id-type="pmid">27104183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dechow</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Carr</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>PW</given-names>
              </name>
            </person-group>
            <article-title>A randomized, double-blind, placebo-controlled trial of sclerosing injections in patients with chronic low back pain.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>38</volume>
            <issue>12</issue>
            <fpage>1255</fpage>
            <page-range>1255-9</page-range>
            <pub-id pub-id-type="pmid">10587555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buchanan</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>DeLuca</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Lammlein</surname>
                <given-names>KP</given-names>
              </name>
            </person-group>
            <article-title>Technical Innovation Case Report: Ultrasound-Guided Prolotherapy Injection for Insertional Achilles Calcific Tendinosis.</article-title>
            <source>Case Rep Orthop</source>
            <year>2016</year>
            <volume>2016</volume>
            <fpage>1560161</fpage>
            <pub-id pub-id-type="pmid">27974984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vangsness</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Farr</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boyd</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dellaero</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>LeRoux-Williams</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy: a randomized, double-blind, controlled study.</article-title>
            <source>J Bone Joint Surg Am</source>
            <year>2014</year>
            <month>Jan</month>
            <day>15</day>
            <volume>96</volume>
            <issue>2</issue>
            <fpage>90</fpage>
            <page-range>90-8</page-range>
            <pub-id pub-id-type="pmid">24430407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poulos</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The limited application of stem cells in medicine: a review.</article-title>
            <source>Stem Cell Res Ther</source>
            <year>2018</year>
            <month>Jan</month>
            <day>02</day>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <pub-id pub-id-type="pmid">29291747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zehnder</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>LL</given-names>
              </name>
            </person-group>
            <article-title>Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin.</article-title>
            <source>Blood</source>
            <year>1990</year>
            <month>Nov</month>
            <day>15</day>
            <volume>76</volume>
            <issue>10</issue>
            <fpage>2011</fpage>
            <page-range>2011-6</page-range>
            <pub-id pub-id-type="pmid">2242423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Landesberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pinsky</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eisig</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>Activation of platelet-rich plasma using thrombin receptor agonist peptide.</article-title>
            <source>J Oral Maxillofac Surg</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>63</volume>
            <issue>4</issue>
            <fpage>529</fpage>
            <page-range>529-35</page-range>
            <pub-id pub-id-type="pmid">15789326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>HUNT</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>BAIRD</surname>
                <given-names>WC</given-names>
              </name>
            </person-group>
            <article-title>Complications following injection of sclerosing agent to precipitate fibro-osseous proliferation.</article-title>
            <source>J Neurosurg</source>
            <year>1961</year>
            <month>Jul</month>
            <volume>18</volume>
            <fpage>461</fpage>
            <page-range>461-5</page-range>
            <pub-id pub-id-type="pmid">13716870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>SCHNEIDER</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>WILLIAMS</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>LISS</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Fatality after injection of sclerosing agent to precipitate fibro-osseous proliferation.</article-title>
            <source>J Am Med Assoc</source>
            <year>1959</year>
            <month>Aug</month>
            <day>08</day>
            <volume>170</volume>
            <issue>15</issue>
            <fpage>1768</fpage>
            <page-range>1768-72</page-range>
            <pub-id pub-id-type="pmid">13672766</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richette</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chevalier</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ea</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Eymard</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Henrotin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ornetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sellam</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cucherat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marty</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hyaluronan for knee osteoarthritis: an updated meta-analysis of trials with low risk of bias.</article-title>
            <source>RMD Open</source>
            <year>2015</year>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>e000071</fpage>
            <pub-id pub-id-type="pmid">26509069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Younus</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of the therapeutic effect of treatment with intra-articular hyaluronic acid in knees for Kashin-Beck disease: a meta-analysis.</article-title>
            <source>Osteoarthritis Cartilage</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>22</volume>
            <issue>6</issue>
            <fpage>718</fpage>
            <page-range>718-25</page-range>
            <pub-id pub-id-type="pmid">24792210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Block</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>US-Approved Intra-Articular Hyaluronic Acid Injections are Safe and Effective in Patients with Knee Osteoarthritis: Systematic Review and Meta-Analysis of Randomized, Saline-Controlled Trials.</article-title>
            <source>Clin Med Insights Arthritis Musculoskelet Disord</source>
            <year>2013</year>
            <volume>6</volume>
            <fpage>57</fpage>
            <page-range>57-63</page-range>
            <pub-id pub-id-type="pmid">24027421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Bhattacharyya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Parrish</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Fredericson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bisson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Altman</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Safety of Intra-Articular Hyaluronic Acid for Knee Osteoarthritis: Systematic Review and Meta-Analysis of Randomized Trials Involving More than 8,000 Patients.</article-title>
            <source>Cartilage</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>1_suppl</issue>
            <fpage>351S</fpage>
            <page-range>351S-363S</page-range>
            <pub-id pub-id-type="pmid">31735075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campbell</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Erickson</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Saltzman</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Mascarenhas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bach</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>NN</given-names>
              </name>
            </person-group>
            <article-title>Is Local Viscosupplementation Injection Clinically Superior to Other Therapies in the Treatment of&#x000a0;Osteoarthritis of the Knee: A Systematic Review of&#x000a0;Overlapping Meta-analyses.</article-title>
            <source>Arthroscopy</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>31</volume>
            <issue>10</issue>
            <fpage>2036</fpage>
            <page-range>2036-45.e14</page-range>
            <pub-id pub-id-type="pmid">25998016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peerbooms</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Sluimer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bruijn</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Gosens</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: platelet-rich plasma versus corticosteroid injection with a 1-year follow-up.</article-title>
            <source>Am J Sports Med</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>255</fpage>
            <page-range>255-62</page-range>
            <pub-id pub-id-type="pmid">20448192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gosens</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Peerbooms</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>van Laar</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>den Oudsten</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Ongoing positive effect of platelet-rich plasma versus corticosteroid injection in lateral epicondylitis: a double-blind randomized controlled trial with 2-year follow-up.</article-title>
            <source>Am J Sports Med</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>39</volume>
            <issue>6</issue>
            <fpage>1200</fpage>
            <page-range>1200-8</page-range>
            <pub-id pub-id-type="pmid">21422467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krogh</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Fredberg</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Stengaard-Pedersen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ellingsen</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Treatment of lateral epicondylitis with platelet-rich plasma, glucocorticoid, or saline: a randomized, double-blind, placebo-controlled trial.</article-title>
            <source>Am J Sports Med</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>625</fpage>
            <page-range>625-35</page-range>
            <pub-id pub-id-type="pmid">23328738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sundman</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Karas</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Della Valle</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tetreault</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Mohammed</surname>
                <given-names>HO</given-names>
              </name>
              <name>
                <surname>Fortier</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>The anti-inflammatory and matrix restorative mechanisms of platelet-rich plasma in osteoarthritis.</article-title>
            <source>Am J Sports Med</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-41</page-range>
            <pub-id pub-id-type="pmid">24192391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riboh</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Saltzman</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Yanke</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Fortier</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Effect of Leukocyte Concentration on the Efficacy of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis.</article-title>
            <source>Am J Sports Med</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>792</fpage>
            <page-range>792-800</page-range>
            <pub-id pub-id-type="pmid">25925602</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Orrego</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Larrain</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rosales</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Valenzuela</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Matas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Durruty</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sudy</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mardones</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Effects of platelet concentrate and a bone plug on the healing of hamstring tendons in a bone tunnel.</article-title>
            <source>Arthroscopy</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>24</volume>
            <issue>12</issue>
            <fpage>1373</fpage>
            <page-range>1373-80</page-range>
            <pub-id pub-id-type="pmid">19038708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Podesta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Crow</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Volkmer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bert</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yocum</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Treatment of partial ulnar collateral ligament tears in the elbow with platelet-rich plasma.</article-title>
            <source>Am J Sports Med</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>41</volume>
            <issue>7</issue>
            <fpage>1689</fpage>
            <page-range>1689-94</page-range>
            <pub-id pub-id-type="pmid">23666850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dines</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>ElAttrache</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Conte</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tomczyk</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Osbahr</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Dines</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Platelet-Rich Plasma Can Be Used to Successfully Treat Elbow Ulnar Collateral Ligament Insufficiency in High-Level Throwers.</article-title>
            <source>Am J Orthop (Belle Mead NJ)</source>
            <year>2016</year>
            <season>Jul-Aug</season>
            <volume>45</volume>
            <issue>5</issue>
            <fpage>296</fpage>
            <page-range>296-300</page-range>
            <pub-id pub-id-type="pmid">27552453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pirvu</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Schroeder</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Peroglio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Verrier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Richards</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Alini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grad</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Platelet-rich plasma induces annulus fibrosus cell proliferation and matrix production.</article-title>
            <source>Eur Spine J</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>745</fpage>
            <page-range>745-53</page-range>
            <pub-id pub-id-type="pmid">24469887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akeda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>An</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Pichika</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Attawia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thonar</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Lenz</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Uchida</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Masuda</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Platelet-rich plasma (PRP) stimulates the extracellular matrix metabolism of porcine nucleus pulposus and anulus fibrosus cells cultured in alginate beads.</article-title>
            <source>Spine (Phila Pa 1976)</source>
            <year>2006</year>
            <month>Apr</month>
            <day>20</day>
            <volume>31</volume>
            <issue>9</issue>
            <fpage>959</fpage>
            <page-range>959-66</page-range>
            <pub-id pub-id-type="pmid">16641770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Yeom</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Koh</surname>
                <given-names>YG</given-names>
              </name>
              <name>
                <surname>Yeo</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CK</given-names>
              </name>
            </person-group>
            <article-title>Anti-inflammatory effect of platelet-rich plasma on nucleus pulposus cells with response of TNF-&#x003b1; and IL-1.</article-title>
            <source>J Orthop Res</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>32</volume>
            <issue>4</issue>
            <fpage>551</fpage>
            <page-range>551-6</page-range>
            <pub-id pub-id-type="pmid">24338609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tyszko</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hecht-Leavitt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Walko</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Intradiscal Platelet-Rich Plasma Injection for Chronic Discogenic Low Back Pain: Preliminary Results from a Prospective Trial.</article-title>
            <source>Pain Med</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>1010</fpage>
            <page-range>1010-22</page-range>
            <pub-id pub-id-type="pmid">26814283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tuakli-Wosornu</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Terry</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boachie-Adjei</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Gribbin</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>LaSalle</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Lutz</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Lumbar Intradiskal Platelet-Rich Plasma (PRP) Injections: A Prospective, Double-Blind, Randomized Controlled Study.</article-title>
            <source>PM R</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-10; quiz 10</page-range>
            <pub-id pub-id-type="pmid">26314234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Monfett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boachie-Adjei</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lutz</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Intradiscal platelet-rich plasma (PRP) injections for discogenic low back pain: an update.</article-title>
            <source>Int Orthop</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>1321</fpage>
            <page-range>1321-8</page-range>
            <pub-id pub-id-type="pmid">27073034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xiong</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>A New Technique for the Treatment of Lumbar Facet Joint Syndrome Using Intra-articular Injection with Autologous Platelet Rich Plasma.</article-title>
            <source>Pain Physician</source>
            <year>2016</year>
            <season>Nov-Dec</season>
            <volume>19</volume>
            <issue>8</issue>
            <fpage>617</fpage>
            <page-range>617-625</page-range>
            <pub-id pub-id-type="pmid">27906940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xiong</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>A Prospective Study Comparing Platelet-Rich Plasma and Local Anesthetic (LA)/Corticosteroid in Intra-Articular Injection for the Treatment of Lumbar Facet Joint Syndrome.</article-title>
            <source>Pain Pract</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>7</issue>
            <fpage>914</fpage>
            <page-range>914-924</page-range>
            <pub-id pub-id-type="pmid">27989008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-138090.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manchikanti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Centeno</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Atluri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Albers</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Malanga</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Abd-Elsayed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jerome</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Aydin</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Beall</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Buford</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Borg-Stein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Buenaventura</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Cabaret</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Calodney</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Candido</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Cartier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Latchaw</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Diwan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dodson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fausel</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Fredericson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gharibo</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Knezevic</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Kosanovic</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lucas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Manchikanti</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mautner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Murala</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Navani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pampati</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pastoriza</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pasupuleti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Philip</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sanapati</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Sand</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Soin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stemper</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wargo</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Hernigou</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Bone Marrow Concentrate (BMC) Therapy in Musculoskeletal Disorders: Evidence-Based Policy Position Statement of American Society of Interventional Pain Physicians (ASIPP).</article-title>
            <source>Pain Physician</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>E85</fpage>
            <page-range>E85-E131</page-range>
            <pub-id pub-id-type="pmid">32214287</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
